KYMR Stock: Price, Earnings History and SEC Filings
Kymera Therapeutics, Inc. (KYMR) last traded at $126.63, up 3.29% on the latest session and up 13.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-1.32 against an analyst estimate of $-1.26, a miss of 4.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
KYMR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-1.32 | $-1.26 | -4.76% |
| Jun 2026 | Aug 5, 2026 | $-0.62 | $-0.64 | +3.13% |
| Mar 2026 | Apr 30, 2026 | $-0.71 | $-0.89 | +20.22% |
| Dec 2025 | Feb 26, 2026 | $-0.97 | $-0.77 | -25.97% |
KYMR beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How KYMR reacts to earnings
Across its last 8 earnings releases, KYMR moved 2.2% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | Before open | +0.07% |
| 2026-08-05 | Before open | +1.04% |
| 2026-04-30 | Before open | -0.54% |
| 2026-02-26 | Before open | +4.80% |
| 2026-01-13 | Before open | +1.42% |
| 2025-11-04 | Before open | +0.32% |
| 2025-08-11 | Before open | -7.24% |
| 2025-05-09 | Before open | -2.27% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
KYMR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $39M | -$311M | -$234M | -794.0% | $-3.69 |
| 2024 | $47M | -$224M | -$207M | -475.6% | $-2.98 |
| 2023 | $79M | -$147M | -$137M | -187.0% | $-2.52 |
| 2022 | $47M | -$155M | -$156M | -330.6% | $-2.87 |
| 2021 | $73M | -$100M | -$131M | -137.6% | $-2.09 |
| 2020 | $34M | -$46M | $79M | -134.0% | $-3.15 |
| 2019 | $3M | -$41M | $17M | -1405.8% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for KYMR
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 27, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 25, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 24, 2026Shareholder vote
- 8-K · Jun 8, 2026Officer or director change
- 10-Q · Apr 30, 2026
- 8-K · Apr 30, 2026Results of operations, Financial statements and exhibits
Insider filing activity
KYMR insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
KYMR news
- Kymera Therapeutics, Inc. Q3 2026 Earnings Call SummaryOct 29, 2026 · app.moby.co
- Kymera (KYMR) Q3 2026 Earnings Call TranscriptOct 29, 2026 · fool.com
- Kymera Therapeutics Q3 Earnings Call HighlightsOct 29, 2026 · marketbeat.com
- Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer TrialOct 29, 2026 · finance.yahoo.com
- Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026Oct 28, 2026 · finance.yahoo.com
- Kymera Therapeutics (KYMR) Nears Earnings With KT 621 In Focus, Is The Stock Still Cheap?Oct 27, 2026 · finance.yahoo.com
- Could You Have Seen The Run In Kymera Stock Coming?Oct 26, 2026 · trefis.com
- Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should KnowOct 26, 2026 · finance.yahoo.com
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. (KYMR) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.